8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 4, 2026·SEC
Material company update
Feb 20, 2026·SEC
KALA BIO, Inc.(KALA)Earnings, Financials & Key Ratios
KALA•NASDAQ
$1.54
Price updated Jul 6, 2026
AboutKala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.Show more
- Revenue$0
- EBITDA-$39M+3.3%
- Net Income-$27M+29.9%
- EPS (Diluted)-3.31+52.6%
- ROE-279.18%+28.1%
KALA Price & Volume
KALA BIO, Inc. (KALA) stock price & volume — 10-year historical chart
Loading chart...
Clinical Pivot Masks Severe Liquidity Exhaustion Risk
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- KALA BIO has transitioned into a high-risk, pre-revenue clinical-stage entity, with its future entirely contingent on the success of the KPI-012 MSC-S platform.
- The company's financial profile is characterized by a massive $696.5 million accumulated deficit and a rapid depletion of its asset base, which fell from $55.9 million in 2023Q4 to $12.3 million by 2026Q1.
- Investors should remain cautious as the firm faces imminent liquidity constraints and potential dilution, given that its cash position has dwindled to a precarious $1.8 million.
Verdict Logic
the company's cash position of only $1.8 million as of 2026Q1 against a history of multi-million dollar quarterly losses suggests an urgent need for dilutive financing to maintain clinical operations.
KALA Growth Metrics
KALA BIO, Inc. (KALA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM44.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM64.86%
Return on Capital
10 Years-86.95%
5 Years-102.06%
3 Years-112.65%
Last Year-172.05%
KALA Recent Earnings
KALA BIO, Inc. (KALA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.14+98.4%
$8.50
Rev
—
—
Q2 2026
Apr 15, 2026Metric
Actual
Est
EPS
$0.08+100.5%
$16.00
Rev
—
—
Q4 2025
Nov 19, 2025Metric
Actual
Est
EPS
$1.07-5.9%
$1.01
Rev
—
—
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$1.71+6.0%
$1.82
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.14vs $8.50+98.4% | — |
| Q2 2026 | Apr 15, 2026 | $0.08vs $16.00+100.5% | — |
| Q4 2025 | Nov 19, 2025 | $1.07vs $1.01-5.9% | — |
| Q3 2025 | Aug 8, 2025 | $1.71vs $1.82+6.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for KALA BIO, Inc. (KALA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.54 | $33.77M | -0.47 | — | — | -279.18% | — | |
| $9.66 | $2.12B | -6.80 | -18.67% | -558.24% | -64.55% | — | |
| $102.82 | $6.69B | 30.15 | 0.5% | 18.05% | 24.33% | — | |
| $44.93 | $1.67B | -320.93 | 36.41% | -5.57% | -33.92% | — | |
| $5.48 | $298.17M | -7.41 | -3.13% | -46.83% | -59.1% | — | |
| $17.32 | $1.97B | -14.20 | 8.28% | -25.66% | -50.82% | — |
Compare KALA vs Peers
KALA BIO, Inc. (KALA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KALA SEC Filings & Documents
KALA BIO, Inc. (KALA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when KALA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KALA Frequently Asked Questions
KALA BIO, Inc. (KALA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is KALA profitable?
KALA BIO, Inc. (KALA) reported a net loss of $19.7M for fiscal year 2025.
Dividend & Returns
What is KALA's return on equity?
KALA BIO, Inc. (KALA) has a return on equity (ROE) of -279.2%. Negative ROE indicates the company is unprofitable.
What is KALA BIO, Inc.'s free cash flow?
KALA BIO, Inc. (KALA) had negative free cash flow of $26.1M in fiscal year 2025, likely due to heavy capital investments.